Shares of Burning Rock Biotech Limited (NASDAQ:BNR - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $8.23, but opened at $8.42. Burning Rock Biotech shares last traded at $8.00, with a volume of 1,662 shares.
Burning Rock Biotech Stock Down 2.4 %
The company has a fifty day simple moving average of $7.64 and a two-hundred day simple moving average of $8.35. The stock has a market capitalization of $822.59 million, a P/E ratio of -9.02 and a beta of 0.18.
Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last posted its earnings results on Thursday, March 28th. The company reported ($2.20) earnings per share for the quarter. The business had revenue of $17.05 million for the quarter. Burning Rock Biotech had a negative return on equity of 71.77% and a negative net margin of 121.79%.
Institutional Trading of Burning Rock Biotech
An institutional investor recently raised its position in Burning Rock Biotech stock. Kynam Capital Management LP lifted its stake in Burning Rock Biotech Limited (NASDAQ:BNR - Free Report) by 10.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,640,914 shares of the company's stock after acquiring an additional 946,488 shares during the quarter. Burning Rock Biotech makes up approximately 0.7% of Kynam Capital Management LP's investment portfolio, making the stock its 18th largest position. Kynam Capital Management LP owned approximately 9.41% of Burning Rock Biotech worth $7,020,000 as of its most recent SEC filing. 30.03% of the stock is currently owned by institutional investors and hedge funds.
Burning Rock Biotech Company Profile
(
Get Free Report)
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
See Also
Before you consider Burning Rock Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Burning Rock Biotech wasn't on the list.
While Burning Rock Biotech currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
